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Assessing tHe effectiveness AnD cost-effectiveness of AuDit AnD 
feeDbAck on PHysiciAn’s Prescribing inDicAtors
Soleymani F.1, Rashidian A.2, Dinarvand R.2, Kebriaeezade A.2, Hosseini M.2, Abdollahi M.2
1Ministry of Health, Tehran, Iran, 2Tehran University of Medical Sciences, Tehran, Iran
Objectives: Improving and promoting rational drug use is a great interest. We 
aimed to assess the effectiveness and cost-effectiveness of prescribing audit and 
feedback intervention in improving physician prescribing. MethOds: A four-arm 
randomized trial with economic evaluation conducted in Tehran. Three interven-
tions (routine feedback, revised feedback, and printed educational material) and 
a no intervention control arm compared. Physicians working in outpatient prac-
tices were randomly allocated to one of the four arms using stratified randomized 
sampling. The interventions were developed based on a review of literature, physi-
cian interviews, current experiences in Iran and with theoretical insights from the 
Theory of Planned Behavior. Effects of the interventions on improving antibiotics 
and corticosteroids prescribing assessed in regression analyses. Cost data assessed 
from a health care provider’s perspective and incremental cost-effectiveness ratios 
calculated. Results: Comparing the new-design feedback arm and the no inter-
vention arm, we observed significant reductions in the proportion of prescriptions 
including Dexamethasone injectable (1.64 difference in percentage change; p value: 
0.006) and Cefixime (0.99 difference in percentage change; p value: 0.01). We also 
observed significant reductions in the printed educational material arm’s propor-
tion of prescriptions including Cefixime (0.93 difference in percentage change; 
p value: 0.04) as compared with the no intervention arm. ICER values correspond-
ing to Dexamethasone injectable and Cefixime were 0.41 and 1.03 US$ per unit 
reduction in the number of prescriptions respectively. cOnclusiOns: According 
to the results of this study, we recommend that a careful attention to the format, 
design and the way the messages are conveyed in feedback forms is an important 
indicator of audit and feedback’s potential success in improving prescribing behav-
ior. Considering the incremental cost-effectiveness ratio, the cost-effectiveness of 
new-design feedback intervention arm has been proved.
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trAining HigH-LeveL LocAL reseArcHers to imProve tHe QuALity of 
cLinicAL stuDies in DeveLoPing countries: cHALLenge AnD strAtegy
Zhou X., Sun X., Li Y.
West China Hospital, Sichuan University, Chengdu, China
Objectives: Analyzing all randomized controlled trials (RCTs) published in The 
Lancet in 2013 to to discuss the influence factors on the publication of high-quality 
clinical studies. MethOds: We included all RCTs published in The Lancet in 2013. 
The information about the research topic and the number of included participants, 
the first author’s region and type of research institution, and the participants’ region 
were collected, and analyzed their proportions. Results: 110 eligible RCTs with 
734,085 participants were included. The top three topics of the RCTs were infec-
tious diseases 22 (20.0%), cardiology and vascular medicine 17 (15.5%), oncology 12 
(10.9%), but the top three number of participants were 210,350 (28.7%) in obstetrics 
and gynaecology, 198,471 (27.0%) in oncology, and 154,637 (21.1%) in infectious dis-
eases. The proportion of RCTs which enrolled participants from developed coun-
tries is 86.4%, only 13.6% ones enrolled participants in developing countries. The 
first authors from the developed and developing countries were 87.3% and 12.7% 
respectively, which was the same as participants. 52.7% RCTs were done by univer-
sities, only 25.2% and 13.6% were conducted by hospitals and research institutions 
respectively. cOnclusiOns: Developing countries have a most heavy burden of 
diseases but serious shortage of high-level clinical researchers. Using results from 
developed countries to guide the prevention and treatment of even the same dis-
eases in the developing countries may not proper due to various local conditions. 
We appeal to promote the cooperation between the universities and hospitals in the 
developed and developing countries. The localization of the training material should 
be encouraged to train more high-level local clinical researchers and produce more 
high-quality clinical evidences for the developing countries through joint-program.
HeALtH cAre use & PoLicy stuDies – Health technology  
Assessment Programs
PHP81
Do HtA Processes correLAte WitH reimbursement recommenDAtions?
Allen N.1, Lipska I.2, Liberti L.3, Salek M.S.1
1Cardiff University, Cardiff, UK, 2Utrecht University, Utrecht, The Netherlands, 3Centre for 
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Objectives: The objective of this study was to compare the Health Technology 
Assessment (HTA) reimbursement recommendations from 6 HTA agencies using 
a HTA process taxonomy. MethOds: Using a previously published categorisation 
process, six HTA agencies were assigned to one of three distinct taxonomic groups 
based on processes for conducting therapeutic value (TV), economic value (EV) or 
appraisal activities: A – TV with independent appraisal; C – TV, EV and appraisal 
combined; I – appraisal independent of TV and EV. Agencies were classified as: 
A- the Health Care Insurance Board (CVZ) in The Netherlands and the French 
National Authority for Health (HAS); C- the National Authority of Medicines and 
Health Products (INFARMED) in Portugal and the Scottish Medicines Consortium 
(SMC); I- the Agency for Health Technology Assessment (AHTAPol) in Poland and the 
National Institute of Care and Health Excellence (NICE) in England. Reimbursement 
recommendations were collected for medicines granted centralised European mar-
keting approval from January 2007 to December 2009 and which were reviewed by 
at least two target HTA agencies. Jurisdictional economic and demographic data 
were collected to further refine the taxonomy. Results: 71 products with 271 
HTA recommendations were categorised by taxonomy to reveal congruence of 86% 
(n= 49) for A, 63% (n= 19) for I, and 44% (n= 25) for C. Congruence between dissimilar 
taxonomies ranged from 47% to 96% and suggest the reimbursement recommen-
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reseArcH on HeALtH services neeD AnD utiLizAtion of tHe rurAL 
eLDerLy Left At Home in sHAAnxi Province, cHinA
Liu J., Wu J., Mao Y.
Xi’an Jiaotong University, Xi’an City, China
Objectives: Based on the survey data of Shaanxi Province in 2012, this paper ana-
lyzed the situation of health services need and utilization of the rural elderly left 
at home (reLAH), and discussed their influencing factors. MethOds: 1) Four-steps 
modeling method. Based on this method, we built four regression models which 
were the logistic regression models of two-week out-patient rate and hospitaliza-
tion rate last year, and the linear regression models of the logarithmic out-patient 
expenses and the logarithmic in-patient expenses. 2) Logistic regression analysis. 
It was used to analyze the influencing factors of health services need and utiliza-
tion of the RELAH. 3) Chi-square test. We used it to make comparison analysis on 
health services need and utilization between the RELAH and the normal rural 
elderly. Results: 1) The health status of the RELAH are poorer, many of their 
health services demands haven’t been got released compared with the normal 
rural elderly, and the features of health services of the rural oldest old left at home 
are high need but low utilization. 2) The influencing factors of health services 
need of the RELAH mainly include education, occupation, income level, age and 
whether living together with their grandchildren. 3) The influencing factors of 
health services utilization of the RELAH mainly include marriage, income level, 
age, accessibility to health services, living together with their grandchildren, being 
required hospitalization last year, suffering from chronic diseases and the types 
of medical institutions for treatments. cOnclusiOns: Combined with research 
results, we give some suggestions. Firstly, perfect the compensation mechanism 
of medical institutions to reduce patients’ medical expenses. Secondly, make the 
land expropriation reasonably, and avoid farmers suffering from the jobless situ-
ation. Thirdly, develop the family doctor system actively. Fourthly, develop the 
county economy, reduce the families’ numbers of the RELAH and ensure them 
have families’ accompanying when ill.
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HeAring tHe PAtient’s voice in HeALtH cAre: A survey AnALysis  
of PAtients’ PercePtions of DifficuLties in sHAreD cLinicAL  
Decision-mAking
Jia P., Zhang L., Mao X., Zhang M.
Sichuan University, Chengdu, China
Objectives: To explore the factors which affect shared decision-making and 
develop strategies to get patients actively involved in clinical decision-mak-
ing. MethOds: The survey was conducted in one of the Third-grade hospitals in 
southwest part of China for a total of 565 patients involved. SPSS 17.0 was used to 
perform data extraction and analysis. Results: The survey yielded to 600 question-
naires with a 94% response rate. There were 68% patients who had some knowledge 
of the disease. Most of the patients (92.94%) have a positive attitude to participate 
in clinical decision making and 95% patients hope to know the medical information 
of treatment. Account for 60.24% patients would like to obtain information from 
doctors. While, only 46.21% patients can achieve the goals. Meanwhile, There were 
79.2 % patients who are satisfied with the current treatment plan. The patients’ big-
gest concerns were: treatment effect, cost and doctors’ skills. The biggest difﬁculties 
that patients worried about were: long-time waiting in out-patient departments 
(50.47%) and limited time to communicate with doctors (37.08%). cOnclusiOns: 
As more and more patients would like to involve in shared decision-making, doctors 
need to provide patients with more choices and help them make a right decision 
in their treatment. A successful bidirectional way between and patients will obtain 
patients’ trust and cooperation.
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Assessment of rurAL HeALtH PurcHAsing ArrAngements in cHinA
Fu P.
Center for Health Management and policy, Shandong University, Jinan, China
Objectives: Strategic purchasing aims at maximizing health system performance 
and takes the health preference of people as basis to decide which interventions 
should be purchased, how and from whom they can buy them. At present China, 
the purchasing arrangements are not perfect and several issues should be resolved 
urgently. Moreover, the limited research findings have not proposed effective solu-
tions. Therefore this research project is considerably necessary and significant. 
The objectives of this study is to describe the purchasing arrangements in current 
China, analyze the factors which block the system performance, and propose what 
roles are purchasers expected to play in progress towards universal health cover-
age (UHC) from the perspective of strategic purchasing. MethOds: This study 
applies the model of multiple principal-agent relationship to the examination 
of relationships among the performers within the new rural cooperative medical 
scheme (NCMS) in China. We obtain information from case study and qualitative 
study by interviewing key people. Three provinces including Qinghai, Henan and 
Shandong have been chosen as our study sites with purposive sampling. In addi-
tion, provincial and county level leaders will also be interviewed. We critically 
assess the actual purchasing performance by comparing it with ideal strategic 
purchasing mechanism, recognize hindering factors which influences the system’s 
performance, and finally propose suggestions for policy making. Results: The 
results indicate that the accessibility, efficiency, and quality of primary health 
services in present China are low. Practice of strategic purchasing is limited and 
the purchasers could not fully represent community’s preference. Meanwhile, 
purchasers are lack of control on health care providers and stewardship of gov-
ernment is not adequate. cOnclusiOns: Enhancement of strategic purchasing 
mechanism needs to better coordinate principle- agent relationships between 
different actors, create appropriate incentives by adopting mixed provider pay-
ment methods and contracting with providers. Key words: Strategic purchasing; 
multiple principal-agent model; financing; people preference.
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took and what additional evidence was requested. Data on 19 projects that entered 
phase III and 30 products achieving first world approval from 2009-2012 were ana-
lysed. Results: For the phase III projects, 63% received HTA scientific advice, of 
which 61% occurred during phase II, with company-sponsored advisory boards 
the being most frequent provider. The main HTA-related requirements included 
in development were patient-reported outcomes (84%), HTA-acceptable endpoints 
(74%), and cost-effectiveness analysis (74%). For licensed products, the median 
time from regulatory submission to reimbursement decision varied from 639 days 
(Australia) to 846 days (Italy). Additional comparators for local HTA submission were 
requested by all jurisdictions except USA. England and France showed the highest 
percentage of products being reimbursed as per the regulatory label (50% and 55% 
respectively). cOnclusiOns: Companies are actively taking scientific advice and 
incorporating HTA requirements into their development process, although they are 
still challenged by divergence in HTA process and decision making across jurisdic-
tions. Benchmarking HTA processes at the product level supports companies in 
driving excellence in risk management and strategic planning.
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comPArison of economic evALuAtion guiDeLines betWeen JAPAn AnD 
otHer AsiAn countries
Millier A.1, Aballea S.1, Toumi M.2, Onishi Y.3, Ikeda S.4
1Creativ-Ceutical, paris, France, 2University of Marseille, Marseille, France, 3Sanofi K. K, Tokyo, 
Japan, 4International University of Health and Welfare, Ohtawara -City, Japan
Objectives: The special committee of cost-effectiveness at the Japanese health 
ministry advisory panel was established in 2012 and the need for economic evalu-
ation guidelines was proposed. The research team funded by the Japanese Ministry 
of Health, Labour and Welfare published the guidelines for economic evaluation of 
health care technologies in 2013. We compared the Japanese guidelines to existing 
guidelines in other Asian countries and to the NICE guidelines (UK). MethOds: We 
searched for and reviewed the Japanese research report and guidelines published 
in China, Taiwan, Thailand and South Korea up to February 2014. Similarities and 
differences between Japanese guidelines and those from other Asian countries as 
well as NICE guidelines were identified. Results: Pharmacoeconomic evaluations 
are mandatory in the UK, South Korea and Thailand, recommended in Taiwan, and 
optional in China. In Japan, economic evaluations are currently not formally consid-
ered in pricing and reimbursement decisions. Japanese guidelines are relatively open, 
leaving much room for decision from analysts. Guidelines from different countries 
were broadly consistent in terms of preferred analytical technique (cost-effectiveness 
analysis), need of systematic reviews of evidence and consideration of effectiveness 
data as well as efficacy; but varied in terms of primary perspective for estimating costs 
(third-party payer in Japan), preferred outcome measure (no systematic use of QALYs 
in Japan, other measures, such as laboratory values, also accepted), preferred methods 
to derive utility values (generic instruments with scoring algorithm developed in 
Japan), and sensitivity analysis methods (probabilistic sensitivity analysis “when pos-
sible”). cOnclusiOns: This comparative exercise provides an overview of economic 
evaluation guidelines adopted by 5 Asian countries and UK. The recommendations 
differed in some aspects, but Japanese guidelines are relatively open, which should 
facilitate adaptations of models between countries. One of the hurdles for adapting 
models is likely to be the variability in approaches recommended to obtain utilities.
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HeALtH tecHnoLogy Assessment in JAPAn: History, current situAtion, 
AnD tHe WAy forWArD
Tokuyama M.1, Gericke C.A.2
1The Wesley Research Institute, Brisbane, Australi,, 2The Wesley Research Institute and University 
of Queensland School of population Health, Brisbane, Australia
Objectives: A rapid growth of health technology assessment (HTA) activities 
among researchers and physicians in Japan is observed since the mid-1980s. 
However, Japan lags behind Europe, Australia, and several Asian countries in imple-
menting national HTA regulations. Although it is generally accepted that low health 
care costs and good health prevail in Japan, population aging, rising costs of medical 
technologies and slow economic growth rates necessitate rethinking the current 
HTA regulations. This study aims to evaluate the history and current situation of 
the Japanese HTA system, and what Japan needs to do in order to successfully 
implement national HTA regulations. MethOds: Past and current Japanese HTA 
regulation are assessed by analysing both English and Japanese publications and 
legal documents, as well as comparing these with the systems in other Asia-Pacific 
countries: Australia, South Korea, Taiwan, Thailand. Results: There are historical, 
social, and biological reasons why Japan has been successful at maintaining the 
world’s longest life expectancy and the lowest infant mortality at relatively low cost 
despite the lack of a comprehensive HTA system. However, implementation of HTA 
regulation would be a key lever in the health system in line with the new economic 
policy introduced by Prime Minister Abe in 2012. Looking at the legal and organisa-
tional structures, implementation and performance of Asia-Pacific HTA systems, 
a comprehensive HTA system for Japan is proposed. cOnclusiOns: HTA systems 
have been rapidly developing in the Asia-Pacific over the last decade. Facing the 
current pressures on the health system, the question is not whether Japan should 
introduce a comprehensive HTA system but what measures she should adopt. The 
experience of other Asia-Pacific countries in implementing national HTA systems 
can help inform the development of an innovative national HTA system in Japan 
that could play a central role in the future of Japanese health care.
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WHAt is tHe stAtus of HeALtH reLAteD QuALity of Life Among meDicAL 
rePresentAtives in inDiA?
Muragundi P.M.1, Kotlo A.2, Maram A.2, Krovvidi S.A.2, Srikanth M.V.2, Udupa N.3, Naik A.N.4
dations by these is likely to be influenced by factors other than process taxon-
omy. cOnclusiOns: This study identified the greatest level of congruence for HTA 
recommendations from the A taxonomy agencies. Other factors likely play a role in 
the divergences of reimbursement recommendations among dissimilar taxonomies, 
which could be better understood by refining the HTA taxonomy characteristics.
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tHe DA vinci surgicAL system: A rAPiD revieW of tHe cLinicAL AnD 
economic eviDence
Yu J.1, Wang Y.2, Li Y.1, Li X.1, Li C.3, Shen J.T.4
1West China Hospital, Sichuan University, Chengdu, China, 2363 Hospital, Aviation Industry 
Corporation of China, Chengdu, China, 3Nuclear Industry 416 Hospital, Chengdu, China, 4Huzhou 
Teachers College, Huzhou, China
Objectives: Da Vinci Surgical System (DVSS) is the most widely studied surgical 
robot in recently years, which is developed to assist surgeons performing surgical 
procedures. However, DVSS is associated with high capital and operating costs. 
Given its limitations, a review of clinical and economic evidence is necessary for 
decision-makers. we conducted a rapid review to evaluate the clinical and cost-
effectiveness of DVSS compared with open procedures and laparoscopic procedures, 
in order to provide the evidence for health decision makers. MethOds: A compre-
hensive search of electronic databases (EMBASE, PubMed, Cochrane Library, Web of 
Science, CINAHL, CNKI, VIP, CBM and Wangfang) and HTA websites were completed 
to October 9, 2013. Two trained reviews independently screened for eligible studies, 
extracted data and assessed quality. Qualitative description was used to report the 
outcomes. Results: After an initial screen of 272 studies, 18 studies (n= 45,516) 
were selected for meeting inclusion criteria: 3 studies with 32,499 patients were 
healthy technology assessments and 15 studies with 13,017 patients were system-
atic reviews. The clinical and cost-effectiveness of DVSS was varied between dis-
eases. Overall, DVSS was shown to be associated with a reduction in operative time, 
length of hospital stay, blood loss, and transfusion rate compared with open and 
laparoscopic surgery on prostatetomy, nephrectomy, and hysterectomy colorectal 
surgery. DVSS was more expensive than open and laparoscopic surgery for the cost 
of acquiring, operating, and maintaining the robotic techniques. Most economic 
studies showed no significant difference was found in cost- effectiveness of DVSS 
comparing with comparators. cOnclusiOns: DVSS may have an impact on several 
clinical outcomes. However, the evidence was limited to systematic review and 
healthy technology assessments. Furthermore, the cost of DVSS is higher than open 
and laparoscopic surgery. Taking all of this evidence together, decisions about the 
robot-assisted surgery need to be made carefully.
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tHe PerformAnce of tHe PrAgmAtic strAtegy to bring in 
PHArmAcoeconomic eviDence for Drugs reimbursement Decisions  
in tAiWAn
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Objectives: Local pharmacoeconomic evidence was seldom included in the manu-
facturers’ new drugs submission in Taiwan before. A series of pragmatic strategies 
were employed to encourage the presentation of local cost-effectiveness analysis 
(CEA) evidence in the dossiers. This study aims at examing the performance of these 
strategies. MethOds: An incentive of mark-up for conducting local CEA studies has 
been announced since 2010 to encourage the pharmaceutical manufacturers to sub-
mit CEA evidence for new drugs reimbursement application. The National Institute of 
Health Technology Assessment (NIHTA) has started to use a self-developed checklist 
to assess the quality of the local CEA evidence presented in the dossiers. The appraisal 
committee would then decide the extent of mark-up based on the assessment results. 
Three epochs were defined as (1) before mark-up epoch: 2008-2009 (No Mark-up 
Epoch), (2) mark-up without checklist epoch: 2010-the mid-2012 (No Checklist Epoch), 
and (3) mark-up with checklist epoch (Checklist Epoch): mid-2012 till 2013. The num-
ber and the quality of local CEA evidence identified from the dossiers submitted by 
the manufacturers in the three epochs were compared. Results: In the No Mark-up 
epoch, none local CEA evidence has been presented in the dossiers. However, 5 and 
7 local CEA studies have been identified from the dossiers in the Mark-up epoch and 
the Checklist epoch, respectively. None out of the 5 local CEA studies has received the 
mark-up, nevertheless, 6 out of the 7 local CEA studies have receive 1% to 5% mark-
up for the reimbursement price. cOnclusiOns: The pragmatic strategy seems an 
effective approach to encourage the manufacturers to present local CEA evidence in 
the dossiers, which could improve the quality of decision making. In addition, the 
capacity of conducting local CEA studies has been gradually established.
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bencHmArking tHe imPAct of HtA on neW meDicines DeveLoPment 
AnD coverAge Decision mAking
Wang T.
CIRS- Centre for Innovation in Regulatory Science, London, UK
Objectives: To evaluate the impact of HTA on the development and market access 
of new pharmaceutical products in Australia, Canada, England, France, Germany, 
Italy, Spain and the USA. MethOds: An annual benchmarking study was devel-
oped in collaboration with 9 multinational pharmaceutical companies to establish 
appropriate developmental performance metrics to identify if scientific advice 
was received, when it was received, from whom and the outcome and specific 
HTA requirements included into the development process. In addition data were 
also collected across 8 jurisdictions (Australia, Canada, England, France, Germany, 
Italy, Spain and the USA) to identify what evidence was submitted, the time it 
